RAltegravir Switch STudy: Effects on Endothelial Recovery
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Treatment with HIV-infection with protease inhibitors is associated with high blood lipids
and higher chance for cardiovascular complications. The RASSTER study aims to investigate the
effect of switching the protease inhibitor lopinavir/ritonavir to raltegravir on vessel wall
function and inflammation,and activation of the immune system. we hypothesize that with this
intervention these parameters will improve. Since decreased vessel wall function and
inflammation are initial steps in the process of atherosclerosis, it is important to know
this data when treating HIV-infected patients.